Genmab A/ S stock (DK0010272202): antibody specialist in focus after latest earnings and pipeline updates

Genmab A/S, the Danish antibody specialist best known for its oncology drug collaborations, has recently updated investors with new quarterly results and pipeline developments, underscoring both the momentum and risks in its high?profile partnership model. The company reported its latest financial figures and provided fresh color on key cancer programs in collaboration with major pharma partners, according to Genmab investor relations as of 05/2026 and coverage by Reuters as of 05/2026.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

Genmab A/S: core business model

Genmab focuses on the research, development and commercialization of antibody-based therapies, especially in oncology. The company’s business model combines proprietary technology platforms with a partnership-driven strategy, under which large pharmaceutical groups typically handle late-stage development and commercialization while Genmab collects milestones and royalties on approved drugs.

One of the earliest and most important pillars of this model is the cancer drug daratumumab, marketed as Darzalex by Johnson & Johnson. Genmab co-discovered the antibody and receives royalties on global sales, which have become a significant and relatively diversified revenue stream as the drug is used across multiple lines of therapy in multiple myeloma, according to Genmab annual reporting as of 02/2025.

Over time, Genmab has broadened its platform beyond classical monoclonal antibodies to include bispecific antibodies and engineered formats aimed at improving tumor targeting and immune activation. This evolution is central to the company’s long-term strategy: instead of relying on one or two blockbuster royalty streams, the management is working to build a multi-product portfolio, supported by several technology platforms and a growing internal pipeline.

In recent quarterly updates, management has reiterated that investment in research and development remains the largest cost item, reflecting both a competitive environment and the company’s ambition to transition from a primarily royalty-based business into a more integrated biopharma player. That shift is especially relevant for US investors, because the United States is the largest market for advanced oncology therapies and a key region for future launches, as discussed in company presentations referenced by Genmab events materials as of 03/2025.

Main revenue and product drivers for Genmab A/S

Genmab’s current revenue mix is dominated by royalties and milestone payments from partnered products. The cornerstone is Darzalex, which has steadily expanded into earlier lines of treatment in multiple myeloma and into additional indications such as light chain (AL) amyloidosis. Growing global sales by its partner translate into rising royalty income for Genmab, although the exact figures depend on tiered royalty rates and regional performance, according to Genmab annual reporting as of 02/2025.

Besides Darzalex, Genmab earns income from other approved antibodies. These include products such as ofatumumab, where Genmab receives royalties from Novartis in indications like multiple sclerosis, as well as newer therapies licensed to partners for oncology or autoimmune diseases. While each of these may be smaller than the Darzalex franchise, together they broaden the royalty base and reduce dependence on a single blockbuster over time.

Another important driver is the company’s own marketed product Tivdak, a tissue factor-directed antibody-drug conjugate for recurrent or metastatic cervical cancer, which Genmab co-commercializes in the United States with Seagen. Tivdak provides direct product revenue and co-promotion income, in contrast to pure royalties, and therefore marks a step toward a more integrated commercial model. The product’s performance and ongoing studies are closely watched by investors given both the medical need in cervical cancer and the competitive pressures in the ADC space, as discussed in oncology conference reports cited by BioSpace as of 04/2025.

Pipeline progress is another key element for Genmab’s valuation. The company has multiple clinical-stage programs, including bispecific antibodies targeting CD3 and various tumor antigens. Success in these programs could lead to new partnerships, milestone payments and ultimately new marketed products. Conversely, clinical setbacks or safety signals could weigh on sentiment and force management to reprioritize R&D spending.

In the latest quarterly earnings release, management confirmed guidance for the current year and highlighted the contribution from core partnered products while also signaling continued high R&D investments. Revenue growth remained tied largely to the performance of existing oncology collaborations, and investors are monitoring whether new launches and label expansions can offset patent life considerations over the medium term, according to Genmab investor update as of 05/2026.

Industry trends and competitive position

Genmab operates in a highly competitive segment of the biotechnology industry, where innovation cycles are fast and clinical data can quickly reshape the commercial landscape. Monoclonal antibodies and antibody-drug conjugates are central tools in immuno-oncology and hematology, but the field now also includes cell therapies, small molecules and emerging modalities such as T-cell engagers. This broader set of options means patients and physicians have more choices, raising the bar for new products to demonstrate clear benefits.

In this environment, Genmab’s historic strength has been its antibody engineering expertise and its ability to craft attractive deals with large pharma companies. Partnerships with groups such as Johnson & Johnson, Novartis and others provide access to global sales networks and regulatory capabilities, while allowing Genmab to retain upside through royalties and milestones. At the same time, reliance on partners introduces an element of execution risk, because Genmab does not always control trial design, commercial strategy or pricing decisions.

Regulatory and pricing dynamics in the United States are particularly important for Genmab’s future. Ongoing debates around drug pricing, Medicare negotiations and reimbursement models can affect the profitability of oncology drugs. A change in the reimbursement environment for high-priced cancer therapies could influence royalty streams over time. Conversely, strong clinical data and demonstration of long-term survival benefits can support reimbursement and help sustain revenue growth even in a tougher pricing environment, as discussed by policy-focused analyses cited by Bloomberg health policy coverage as of 04/2025.

Why Genmab A/S matters for US investors

For US investors, Genmab’s American depositary shares listed on Nasdaq provide access to a European biotech company with substantial economic exposure to the US oncology market. Most of the major partnered products, including Darzalex and Tivdak, generate a significant portion of their sales in the United States. As a result, Genmab’s revenue and cash flow trends are closely linked to US treatment patterns, regulatory decisions and reimbursement frameworks, according to Genmab investor relations as of 05/2026.

In addition, Genmab regularly participates in major US medical conferences such as ASCO and ASH, where new clinical data sets are presented. These events can act as catalysts for the stock because positive or negative data from pivotal or early-stage trials can influence expectations for future approvals and partnership deals. For investors who follow the broader US biotech sector, Genmab offers a way to gain exposure to antibody-based innovation while partly diversifying geographic risk through its Danish base.

However, US investors should also consider the implications of currency movements, as the company reports in Danish kroner while the ADS trades in US dollars. Fluctuations in exchange rates can influence reported results and valuations when translated into dollars. Moreover, tax considerations for US holders of foreign shares or ADS structures can differ from those of domestic equities and may require individual assessment.

Risks and open questions

Like most biotech companies, Genmab faces a variety of risks that can influence its share price. Clinical development risk is central, as setbacks in key trials or safety problems could delay or prevent approvals and force pipeline reprioritization. Because some programs are conducted in partnership with large pharma companies, Genmab may have limited control over trial timelines or strategic shifts at its partners, which can add complexity.

Another concern relates to concentration risk in revenue. While management has made progress in broadening the portfolio, a significant share of Genmab’s income still stems from a relatively small number of products. The longer-term impact of patent expirations, biosimilar competition and shifts in standard of care remains an open question that investors will monitor through guidance updates and strategic communications, as noted by coverage from Reuters as of 05/2026.

Regulatory and pricing developments are further sources of uncertainty. Changes in US reimbursement rules or European health technology assessments could influence the attractiveness of high-cost oncology drugs. Furthermore, broader market factors, such as risk appetite for growth stocks, interest rate movements and sector rotations, can affect biotech valuations independent of company-specific news.

Conclusion

Genmab A/S combines a proven antibody technology platform with a partnership-driven strategy that has already yielded multiple marketed therapies and substantial royalty income. Recent earnings and pipeline updates highlight both the strength of its core oncology collaborations and the ongoing need for heavy R&D investment to support future growth. For US-focused investors, the company offers exposure to advanced cancer treatments and major American markets through a European-based biotech with global reach. At the same time, concentration risk in a few leading products, regulatory and pricing uncertainties and typical biotech development risks remain important factors that can drive share price volatility over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.